Pulmonary Disorders

David Askew

Francis X McCormack Jr, MD

Int Med-Pulmonary

Taylor Professor & Division Director

Research Summary

The focus of our laboratory is the structure and function of pulmonary surfactant proteins. We are particularly interested in the antimicrobial, antioxidant, and immunomodulatory roles of surfactant proteins A and D in the alveolar space.

Recent Publications

Young LR, Franz DN, Nagarkatte P, Fletcher CD, Wikenheiser-Brokamp KA, Galsky MD, Corbridge TC, Lam AP, Gelfand MJ, McCormack FX. Utility of FDG-PET inSporadic and Tuberous Sclerosis Associated Lymphangioleiomyomatosis. Chest. 2009 Apr 6. [Epub ahead of print] PubMed PMID: 19349386.

Schmithorst VJ, Altes TA, Young LR, Franz DN, Bissler JJ, McCormack FX,Dardzinski BJ, Brody AS. Automated algorithm for quantifying the extent of cysticchange on volumetric chest CT: initial results in Lymphangioleiomyomatosis. AJRAm J Roentgenol. 2009 Apr;192(4):1037-44. PubMed PMID: 19304711.

Kinder BW, Brown KK, McCormack FX, Ix JH, Kervitsky A, Schwarz MI, King TE Jr.Serum surfactant protein-A is a strong predictor of early mortality in idiopathicpulmonary fibrosis. Chest. 2009 Jun;135(6):1557-63. Epub 2009 Mar 2. PubMed PMID:19255294; PubMed Central PMCID: PMC2716710.

McCormack FX. Lymphangioleiomyomatosis: a clinical update. Chest. 2008Feb;133(2):507-16. Review. PubMed PMID: 18252917.

Young LR, Pasula R, Gulleman PM, Deutsch GH, McCormack FX. Susceptibility ofHermansky-Pudlak mice to bleomycin-induced type II cell apoptosis and fibrosis.Am J Respir Cell Mol Biol. 2007 Jul;37(1):67-74. Epub 2007 Mar 15. PubMed PMID:17363777; PubMed Central PMCID: PMC1899346.

 

"));